Global Autoinjectors Market - 2023-2030

Market Overview

Global Autoinjectors Market reached US$ 8.7 billion in 2022 and is expected to reach US$ 29.7 billion by 2030 growing with a CAGR of 17.2% during the forecast period 2023-2030. The global autoinjectors market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of chronic diseases such as cancer and diabetes, rising patient healthcare expenditure and growing research and development activities.

These are important classes of medical devices that can deliver drugs through the subcutaneous or intramuscular route. They can be easily self-administered, and accurate doses can be given. It is an immediate treatment for emergency conditions such as anaphylaxis, migraine, and other chronic diseases such as diabetes, multiple sclerosis, rheumatoid arthritis, and others.

Market Dynamics

An increase in the Incidence of Multiple Sclerosis is Boosting the Market Growth

An increase in the incidence of multiple sclerosis cases is playing a major role in boosting market growth. Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body.

An increase in the number of MS patients will increase the usage of autoinjectors. For instance, according to the MS Discovery Forum, an estimated 2.5 million people live with multiple sclerosis worldwide. An estimated 200 new cases are diagnosed each week in the United States. Thus, an increase in the number of MS cases is driving the market growth.

An Increase in the Geriatric Population is Magnifying the Market Growth

The increase in the incidence of the geriatric population is expanding the growth of the market. The age factor will influence the market. As there is an increase in aged people, they cannot go for hospitalization for a long period. Aged people are more prone to diseases such as asthma, diabetes, and many others.

In order to avoid the risks, aged groups will prefer convenient methods. Thus, an increase in the number of aged population will drive the market. For instance, according to NIH, elderly patients have the highest reported asthma-related mortality at 51.3 per million persons. Thus increase in the number of older population will expand the market growth.

Complications Associated with the Devices will Decline the Market Growth

The complications associated with the use of the devices can decline the growth of the market. There are a number of side effects and complications associated with the use of auto-injectors. For instance, according to the European Society of Cardiology, the side effects associated with auto-injector are fast/pounding heartbeat, nervousness, sweating, nausea, vomiting, trouble breathing, headache, dizziness, anxiety, shakiness, or pale skin may occur. Thus, an increase in the complications of the devices can affect the market negatively.

COVID-19 Impact Analysis

The COVID-19 epidemic has quickened the trend of self-injection, allowing patients to become more active and in control of their treatment. The direction has promoted newer technologies in the autoinjectors market for enhanced injection speed regulation, injection site pain, and treat anxiety.

In addition, the new products launched by key players are driving the market during the COVID-19 pandemic. For instance, in April 2020, Teva Pharmaceuticals USA, Inc. announced that the autoinjector device for AJOVY (fremanezumab-vfrm) injection is available in the United States. AJOVY is implied for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.

Also, in September 2021, Novartis reported data from an international Phase IIIb study, which delivered treatment with Cosentyx (secukinumab) 300 mg in a 2 mL autoinjector (UnoReady pen) resulted in high effectiveness and proper administration in adults with mild to severe plaque psoriasis1. These data were presented at the European Academy of Dermatology and Venereology's 30th Anniversary Congress.

Moreover, the broader drug delivery market has historically shown consistent, healthy growth, despite the grim realities of the pandemic. As the world begins to recover from the long-lasting effects of COVID-19 and approaches a period of greater stability and normality, markets are expected to flourish.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the Autoinjectors Market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the Autoinjectors Market growth over the forecast period.

Segment Analysis

The autoinjectors market is segmented based on type, application, and end user.

The Type-2 Diabetes Mellitus Segment Accounts for Approximately 34.7% of the Autoinjectors Market Share

Due to the rise in the number of type-2 diabetic patients diseases, the segment holds the highest market share. For instance, according to Healthline, about 1.4 million new cases of diabetes are diagnosed in the United States every year. More than one in every ten adults who are 20 years or older has diabetes. For seniors (65 years and older), that figure rises to more than one in four.

Geographical Analysis

Europe accounted for Approximately 28.4% of the Market Share Owing to Technological Advancements

The rise in collaborations, clinical trials, and innovation of new devices is holding this region in this position. A number of clinical trials and approvals have been taking place in this region in order to make patients available for a number of treatments.

For instance, Aptar Pharma teams up with BD to develop a novel auto-injector. Aptar Pharma has signed an exclusive development and license agreement with BD Becton, Dickinson, and Company (BD). Thus, the increase in company collaborations, technological advancements, and new innovations is raising the growth of the market.

Competitive Landscape

The major global players in the autoinjectors market include: AbbVie, Amgen, Biogen Idec, AstraZeneca, Mylan, Pfizer, Teva Pharmaceuticals, Merck & Co, Johnson & Johnson, and Becton Dickinson and Company among others.

Why Purchase the Report?

• To visualize the auto-injector segmentation based on type, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Autoinjectors Market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The Autoinjectors Market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies